This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CORONA Remedies, a Gujarat-based pharmaceutical company that recently listed on NSE and BSE on December 15, 2025, reported its first set of quarterly results post-IPO. Consolidated revenue from operations grew 15.1% YoY to ₹361.13 Cr in Q2 FY26 and 17.0% YoY to ₹707.67 Cr in H1 FY26. Profit after tax rose 21.8% YoY to ₹52.32 Cr in Q2 and 35.1% YoY to ₹98.52 Cr in H1 FY26. EBITDA for Q2 stood at ₹78.47 Cr (margin 21.7%) and H1 at ₹148.25 Cr (margin 20.9%). Return metrics were strong with annualised RoE of 31.1% and RoCE of 49.7%. Operating cash flow for H1 was healthy at ₹113.44 Cr (76.5% of EBITDA). The statutory auditor Deloitte Haskins & Sells LLP issued an unqualified limited review report on both standalone and consolidated results.
Strong debut quarter with double-digit revenue growth, expanding PAT growth, and high return ratios. The clean auditor review and first post-IPO disclosure are positive for investor confidence, though the stock may already reflect much of this given the recent listing.
| Q3 FY26 | Year ago | Change | |
|---|---|---|---|
| Revenue | ₹342.4 Cr | — | — |
| Operating profit | ₹72.05 Cr | — | — |
| Profit after tax | ₹41.27 Cr | — | — |
| EBITDA margin | 18.7% | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income. No year-ago figures on this basis yet, so no comparison.